These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1740756)

  • 1. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies.
    Arendrup M; Nielsen C; Hansen JE; Pedersen C; Mathiesen L; Nielsen JO
    J Acquir Immune Defic Syndr (1988); 1992; 5(3):303-7. PubMed ID: 1740756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
    Moog C; Fleury HJ; Pellegrin I; Kirn A; Aubertin AM
    J Virol; 1997 May; 71(5):3734-41. PubMed ID: 9094648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.
    Albert J; Abrahamsson B; Nagy K; Aurelius E; Gaines H; Nyström G; Fenyö EM
    AIDS; 1990 Feb; 4(2):107-12. PubMed ID: 2328092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
    Ruppach H; Nara P; Raudonat I; Elanjikal Z; Rübsamen-Waigmann H; Dietrich U
    J Virol; 2000 Jun; 74(12):5403-11. PubMed ID: 10823844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HIV-1 V3 domain on field isolates: participation in generation of escape virus in vivo and accessibility to neutralizing antibodies.
    Arendrup M; Akerblom L; Heegaard PM; Nielsen JO; Hansen JE
    Arch Virol; 1995; 140(4):655-70. PubMed ID: 7794110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion.
    Tsang ML; Evans LA; McQueen P; Hurren L; Byrne C; Penny R; Tindall B; Cooper DA
    J Infect Dis; 1994 Nov; 170(5):1141-7. PubMed ID: 7963706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
    Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
    J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual.
    Montefiori DC; Altfeld M; Lee PK; Bilska M; Zhou J; Johnston MN; Gao F; Walker BD; Rosenberg ES
    J Immunol; 2003 Apr; 170(7):3906-14. PubMed ID: 12646660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between susceptibility of primary HIV-1 isolates to autologous and heterologous neutralizing antibodies. Hospital Evandro Chagas AIDS Clinical Research Group.
    Bongertz V; Costa CI; Santos VG; João Filho EC; Galvão-Castro B; Morgado MG
    AIDS; 1997 Jul; 11(8):969-75. PubMed ID: 9223730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1.
    Geffin R; Hutto C; Andrew C; Scott GB
    Virology; 2003 Jun; 310(2):207-15. PubMed ID: 12781708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus.
    Montefiori DC; Zhou IY; Barnes B; Lake D; Hersh EM; Masuho Y; Lefkowitz LB
    Virology; 1991 Jun; 182(2):635-43. PubMed ID: 1708933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain.
    Zwart G; Back NK; Ramautarsing C; Valk M; van der Hoek L; Goudsmit J
    AIDS Res Hum Retroviruses; 1994 Mar; 10(3):245-51. PubMed ID: 8018385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of HIV-1 group-specific neutralizing antibodies after seroconversion.
    McKnight A; Clapham PR; Goudsmit J; Cheingsong-Popov R; Weber JN; Weiss RA
    AIDS; 1992 Aug; 6(8):799-802. PubMed ID: 1418776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals.
    Kelly HR; Urbanski M; Burda S; Zhong P; Konings F; Nanfack J; Tongo M; Kinge T; Achkar J; Nyambi P
    Hum Antibodies; 2005; 14(3-4):89-99. PubMed ID: 16720979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.
    Deeks SG; Schweighardt B; Wrin T; Galovich J; Hoh R; Sinclair E; Hunt P; McCune JM; Martin JN; Petropoulos CJ; Hecht FM
    J Virol; 2006 Jun; 80(12):6155-64. PubMed ID: 16731954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.
    Hioe CE; Xu S; Chigurupati P; Burda S; Williams C; Gorny MK; Zolla-Pazner S
    Int Immunol; 1997 Sep; 9(9):1281-90. PubMed ID: 9310831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants.
    Dickover R; Garratty E; Yusim K; Miller C; Korber B; Bryson Y
    J Virol; 2006 Jul; 80(13):6525-33. PubMed ID: 16775339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1.
    Kliks SC; Shioda T; Haigwood NL; Levy JA
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11518-22. PubMed ID: 7505441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of autologous neutralizing antibodies in the cerebrospinal fluid of HIV-1 infected individuals.
    von Gegerfelt A; Chiodi F; Keys B; Norkrans G; Hagberg L; Fenyö EM; Broliden K
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1133-8. PubMed ID: 1503825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.